Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
153Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $727.33M | $-108.03M | $-4.20 |
| 2024 | $660.57M | $-78.73M | $-3.10 |
| 2023 | $591.64M | $-87.97M | $-3.50 |
| 2022 | $509.73M | $-144.25M | $-5.80 |
| 2021 | $484.33M | $-8.35M | $-0.35 |
Social Signal Score
Earnings
Tue, Oct 27(in 2 months)
Consensus estimate $0.06 per share
Typical surprise +41.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.05 vs $0.03beat
- Tue, Apr 28$0.01 vs $0.01beat
- Tue, Feb 17$0.06 vs $0.04beat
- Tue, Oct 28$0.03 vs $0.02beat
- Tue, Jul 29$0.03 vs $0.03beat
- Tue, Apr 29$-0.08 vs $-0.02miss
Estimates and results for NEO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
NEOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (4)
- Newsnewsfilecorp.com·3d ago·Neutral
NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas--(Newsfile Corp. - August 12, 2026) - NeOnc Technologies Holdings (NASDAQ: NTHI) reported encouraging Phase 2a results for intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, showing a 48.9% six-month progression-
View source ↗ - Newsglobenewswire.com·3d ago·Neutral
NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma Company to request a Type B meeting with the FDA to align on a registrational path in a setting with no approved targeted therapy — Study met its primary endpoint: six-month progression-free survival of 48.9% versus a pre-specified 20% benchmark for standard of care (p = 0.0047) — Median overall survival of 26.09 months; 86.7% of patients alive at six months — Five of 24
View source ↗ - Newsmarketbeat.com·3d ago·Neutral
Neo Performance Materials Q2 Earnings Call Highlights Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, favorable pricing and lower conversion costs across its business segments, while reaffirming expectations to reach the high end of its increased 2026 adjusted EBITDA guidance.
View source ↗ - Newsglobenewswire.com·5d ago·Neutral
NeOnc Technologies to Host Investor Conference Call to Discuss Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma NeOnc (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, August 12, 2026, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
View source ↗